Top Medical Searches

Current Medical News

FDA Approves Netspot (gallium Ga 68 dotatate) Imaging Agent to Detect Rare Neuroendocrine Tumors

June 1, 2016 — The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive… Read More..

May 31st, 2016

FDA Approves Netspot (gallium Ga 68 dotatate) Imaging Agent to Detect Rare Neuroendocrine Tumors

June 1, 2016 — The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive… Read More..

May 31st, 2016

FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis

Princeton, NJ – May 31, 2016 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,… Read More..

May 31st, 2016

Teva Receives Complete Response Letter for NDA for SD-809 for the Treatment of Chorea Associated with Huntington Disease

JERUSALEM–(BUSINESS WIRE)–May 31, 2016– Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug… Read More..

May 31st, 2016

Teva Receives Complete Response Letter for NDA for SD-809 for the Treatment of Chorea Associated with Huntington Disease

JERUSALEM–(BUSINESS WIRE)–May 31, 2016– Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug… Read More..

May 31st, 2016
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us